Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) that your body absorbs much more efficiently than regular thiamine supplements. It’s most commonly used for diabetic nerve pain and other complications of diabetes, though researchers have also studied it for cognitive decline. The evidence is promising in some areas and mixed in others, so understanding what the research actually shows matters before you spend money on it.
How Benfotiamine Works in the Body
Regular thiamine dissolves in water, which limits how much your body can absorb at once. Benfotiamine bypasses that limitation because it’s fat-soluble, reaching much higher levels inside your cells. Once absorbed, it gets converted into thiamine diphosphate, the active form your cells use.
Thiamine diphosphate activates an enzyme called transketolase, and this is where benfotiamine’s main therapeutic value comes from. In people with high blood sugar, excess glucose creates harmful compounds called advanced glycation end-products (AGEs). These sticky, damaged molecules accumulate in blood vessels, nerves, kidneys, and eyes, driving much of the long-term damage diabetes causes. Transketolase redirects the raw materials that would become AGEs into a harmless metabolic pathway, effectively reducing AGE buildup in tissues. This is why nearly all of benfotiamine’s studied benefits relate to diabetes.
Diabetic Nerve Pain
Nerve damage in the hands and feet is one of the most common complications of diabetes, causing burning, tingling, and numbness. This is the condition benfotiamine has been studied for most extensively, and the results are genuinely mixed.
Several short-term studies lasting 3 to 12 weeks found that high-dose benfotiamine (up to 600 mg per day) improved symptom scores in people with diabetic nerve damage. Patients reported less pain and better sensation. However, a longer and more rigorous trial published in Diabetes Care followed 67 people with type 1 diabetes for 24 months on 300 mg per day or placebo. Despite significantly improving thiamine levels in the body, benfotiamine produced no measurable improvements in nerve conduction or inflammatory markers compared to placebo.
This gap between short-term symptom relief and long-term nerve function improvement is important. Benfotiamine may help some people feel better in the near term, but the evidence that it reverses or halts the underlying nerve damage is weak. It’s possible the short-term benefits reflect a real but modest anti-inflammatory effect that doesn’t translate into structural nerve repair over time.
Kidney and Eye Protection in Diabetes
Because AGEs damage small blood vessels throughout the body, researchers have looked at whether benfotiamine can protect the kidneys and eyes. A few small randomized studies found that 120 to 900 mg per day of benfotiamine decreased urinary albumin excretion, a marker of early kidney damage. That’s a meaningful finding, since catching kidney problems early gives you the best chance of slowing them down.
But the picture isn’t clear-cut. Another study using 900 mg per day found no effect on urinary albumin or another kidney injury marker. The animal research on retinopathy (diabetic eye disease) looks encouraging, but human trials specifically measuring eye outcomes are limited. The AGE-reduction mechanism makes biological sense for protecting small blood vessels, yet the clinical proof hasn’t caught up to the theory.
Cognitive Decline and Alzheimer’s Disease
Benfotiamine has attracted interest as a potential treatment for Alzheimer’s disease, partly because the brains of Alzheimer’s patients show reduced ability to use glucose for energy, a problem thiamine-dependent enzymes could theoretically help with.
A Phase 2 pilot study tested 600 mg of benfotiamine daily for one year in 71 people with confirmed brain amyloid plaques and mild cognitive impairment or mild Alzheimer’s. The trial missed its primary goal: the benfotiamine group showed 43 percent slower cognitive decline on the main test used, but this difference wasn’t statistically significant. One secondary measure of daily functioning did show a significant 77 percent slowing of decline, and brain imaging suggested improved glucose use in the brain, particularly in people without the ApoE4 gene variant that raises Alzheimer’s risk.
A larger trial in China with 302 Alzheimer’s patients taking benfotiamine alongside standard medication also found no significant benefit overall. An exploratory analysis suggested a dose-dependent benefit in people with moderate Alzheimer’s (but not mild), hinting that it might help at a specific disease stage. These are intriguing signals, not proof. The cognitive benefits remain unconfirmed, and no one should rely on benfotiamine as an Alzheimer’s treatment based on current data.
Typical Dosages Used in Research
Clinical trials have used a wide range of doses, from 120 mg to 900 mg per day. The most common doses are 300 mg daily for general supplementation and 600 mg daily in studies targeting more aggressive outcomes like cognitive decline or neuropathy. Some trials combined benfotiamine with other B vitamins, making it harder to isolate its individual contribution.
There’s no officially established therapeutic dose, since benfotiamine is sold as a dietary supplement rather than a prescription medication. Most over-the-counter products contain 150 to 300 mg per capsule.
Safety and Side Effects
Benfotiamine has a reassuring safety profile across the studies done so far. In clinical trials, the number of people experiencing side effects was similar in both the benfotiamine and placebo groups. The only treatment-related issues reported were mild gastrointestinal discomfort in a small number of patients and occasional skin or allergic reactions. A meta-analysis of vitamin B therapy in diabetic kidney disease also found that treatment was well tolerated with only mild side effects in studies lasting over six months.
Long-term safety data beyond two years is limited, which is worth keeping in mind if you plan to take it indefinitely. No drug interactions with benfotiamine have been formally identified, but because it converts to thiamine in the body, and thiamine can lower blood pressure and blood sugar slightly, people already taking medications for those conditions should be aware of potential additive effects.
Who Benefits Most
The strongest case for benfotiamine is in people with diabetes who want to reduce AGE-related damage, particularly those experiencing early signs of nerve pain or kidney stress. The biological mechanism is well understood, and the short-term evidence for symptom improvement in neuropathy is consistent, even if the long-term nerve function data is disappointing.
For people without diabetes, the rationale for taking benfotiamine is much thinner. AGE accumulation does happen with normal aging, but the degree is far less than in uncontrolled diabetes, and no trials have shown meaningful benefits in non-diabetic populations. The cognitive data is too preliminary to justify using it for brain health outside of a clinical trial. If you’re simply concerned about getting enough thiamine, a standard B-complex vitamin is sufficient for most people, since benfotiamine’s advantage is specifically its ability to flood cells with much higher thiamine levels than regular supplements can achieve.